الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Chronic hepatitis C virus (HCV) is a global health burden with hepatic and extrahepatic systemic affection including cardiovascular system .Egypt has the highest prevalence of HCV in the world and it started treatment with direct-acting antiviral (DAAs) in national regimen of the 100 Million Healthy Lives campaign, screening around 49 million adults and 7 million school-age children for both HCV and non-communicable diseases
Objective: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients.
Methods: The prospective cohort study was conducted at Kafrelsheikh University Hospital, Egypt, from December 2019 to December 2021, and comprised adult patients of either gender with chronic hepatitis C virus and with minimum ejection fraction 40%. 200 patients were classified into groups according to their cardiovascular risk. group 1 had individuals with no risk factors, group 2 had patients with many risk factors, group 3 had patients with only hypertension, group 4 had those with diabetes alone, and group 5 comprised smokers. All the patients were evaluated initially and at 12 weeks of combination of sofosbuvir 400 mg once daily dose and daclatasvir 60 mg once daily dose
Results: Of the 200 included patients ,there were non-significant changes in the incidence of angina, arrhythmias or progression of dyspnoea, Echocardiography showed non-significant changes in mean ejection fraction, global longitudinal strain , diastolic dysfunction and pulmonary artery pressure.